)

Sichuan Kelun-Biotech Biopharmaceutical (6990) investor relations material
Sichuan Kelun-Biotech Biopharmaceutical H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Revenue for the first half of 2025 was RMB950.4 million, down 31.3% year-over-year, mainly due to lower milestone payments from license and collaboration agreements.
Net loss for the period was RMB145.2 million, compared to a profit of RMB310.2 million in the prior year; adjusted loss was RMB69.4 million.
Achieved significant commercialization milestones with multiple product launches and regulatory approvals in oncology and immunology, including first-in-class ADCs and mAbs for lung, breast, and nasopharyngeal cancers.
Expanded global clinical collaborations, notably with MSD, and out-licensed key assets for international development.
Included in major global equity indexes and completed a substantial H-share follow-on financing round.
Financial highlights
Gross profit for 1H25 was RMB660.0 million, with gross margin decreasing to 69.4% from 77.9% year-over-year.
R&D expenses for 1H25 totaled RMB611.5 million, down 6.3% year-over-year; selling and distribution expenses rose 334.8% to RMB178.9 million.
Cash and financial assets totaled RMB4,527.8 million as of June 30, 2025, up 47.2% from year-end 2024.
Net cash generated from financing activities in 1H25 was RMB1,774.4 million, mainly from a June 2025 share placement.
No borrowings; gearing ratio not applicable due to excess cash over liabilities.
Outlook and guidance
Focus on advancing differentiated pipelines targeting high unmet medical needs, especially in oncology and non-oncology diseases.
Plans to launch trastuzumab botidotin in China and file NDA for A400 in H2 2025.
Continued investment in R&D, AI-enabled drug discovery, and expansion of global partnerships.
Ongoing efforts to optimize commercialization strategies and expand market access, with expectations for higher sales in the second half, especially from lung cancer indications.
Anticipates operational costs to decrease as products gain medical insurance coverage.
Next Sichuan Kelun-Biotech Biopharmaceutical earnings date

Next Sichuan Kelun-Biotech Biopharmaceutical earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage